89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

NCT03556046 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Carcinoma

Interventions

DIAGNOSTIC_TEST: 89Zr-Girentuximab

Sponsor

Radboud University Medical Center

Collaborators

[object Object]
[object Object]